Exploring the link between stroke and adrenal incidentalomas
If Adrenal Incidentalomas Have the Influences to Occur and Progress in Patients With Stroke
This study is trying to see if having adrenal incidentalomas affects the risk of disability and death in stroke patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Xuanwu Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05237817 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the association between adrenal incidentalomas (AIs) and stroke, focusing on the risk of disability and death in stroke patients with AIs. It consists of two parts: a retrospective cohort study analyzing data from stroke patients between April and September 2021, and a prospective cohort study recruiting stroke patients from March 2022 to February 2024. The study aims to measure levels of autonomous cortisol secretion in these patients and assess the standardized incidence rate of AIs. Detailed information regarding stroke characteristics and patient profiles will be recorded throughout the study.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with stroke, including those with cerebral infarction, intracerebral hemorrhage, or subarachnoid hemorrhage.
Not a fit: Patients with metastatic cancer, adrenal incidentalomas smaller than 1 cm, or those on specific glucocorticoid treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the risks associated with adrenal incidentalomas in stroke patients, potentially guiding better management and treatment strategies.
How similar studies have performed: While the association between adrenal incidentalomas and stroke is not extensively studied, this investigation aims to fill a gap in existing literature, making it a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * stroke disease , such as Cerebral infarction、Intracerebral hemorrhage and Subarachnoid hemorrhage. Exclusion Criteria: * presence of metastatic cancer; * AIs smaller than 1 cm; * nonadenoma lesions, such as myelolipomas,hemorrhages, and cysts; * oral glucocorticoid treatment with more than single doses in the past 3 months; * use of inhaled steroids or medication affecting dexamethasone metabolism; * systemic estrogen treatment.
Where this trial is running
Beijing
- Hao Yan — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Hao Yan, Dr.
- Email: yanhurology@qq.com
- Phone: +86-13651341058
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.